Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039916 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT07039916: Recruiting Phase 3 study of Generalized Myasthenia Gravis, sponsored by Immunovant Sciences.
NCT07039916 is a Phase 3 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 231 participants, above the 122-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07039916, a Phase 3 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
California
- Site Number - 1010 - Carlsbad
- Site Number - 1028 - Irvine
- Site Number - 1023 - Los Angeles
- Site Number - 1029 - Rancho Mirage
- Site Number - 1004 - San Francisco
Florida
- Site Number - 1006 - Clearwater
- Site Number - 1037 - Ormond Beach
- Site Number - 1002 - Port Charlotte
- Site Number - 1050 - Rockledge
- Site Number - 1007 - Tampa
Arizona
- Site Number - 1017 - Phoenix
- Site Number - 1025 - Scottsdale
- Site Number - 1042 - Tucson
Georgia
- Site Number - 1014 - Atlanta
- Site Number - 1043 - Augusta
Alabama
- Site Number - 1041 - Mobile
Colorado
- Site Number - 1027 - Fort Collins
Connecticut
- Site Number - 1001 - New Haven
District of Columbia
- Site Number - 1024 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT07039916 shows while recruiting
NCT07039916 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, above the 122-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (89% higher).
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07039916 names 20 study sites across 9 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07039916 about?
NCT07039916 is a clinical study titled "Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis". The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
What is the current status of trial NCT07039916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2025-05-27. Estimated completion is 2028-12.
What conditions does trial NCT07039916 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT07039916?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT07039916?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07039916 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07039916's enrollment target sits among peer trials
231 6th of 26 higher than 21 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI